NASDAQ$TSHA

Taysha Gene Therapies Inc · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

TSHA reported Q3 2025 revenue of $5.0M, a net loss of $55.0M.

For Q3 2025, TSHA reported Revenue was $5.0M, net loss was $55.0M. Management discusses operating performance, liquidity, and outlook in the quarterly filing.

  • Revenue $5.0M for Q3 2025.
  • Net loss $55.0M.
  • MD&A covers liquidity, capital allocation, and sector-specific risks.

Headline financials

Total Revenue

$0.00

Previous: $1.79M-100.0%
EPS (adj)

-$0.09

Previous: -$0.10+10.0%
Capital Expenditures

-$488K

Previous: -$376K-29.8%
Free Cash Flow

-$33.2M

Previous: -$25.9M-28.3%
Net Income

-$32.7M

Previous: -$25.5M-28.2%
Operating Income

-$34M

Previous: -$25.9M-31.4%
Gross Profit

$0.00

Previous: $1.79M-100.0%
Cash & Equivalents

$297M

Previous: $158M+88.6%
Total Assets

$317M

Previous: $180M+75.7%

Revenue & EPS history

Taysha Gene Therapies · Revenue · Quarterly

$0

Q3 2025-100%vs Q3 2024
Beat estimate in 8 of 11 quarters(73%)
ActualEstimate

Forward guidance

Outlook focuses on cash runway, pipeline milestones, and cost discipline toward profitability.

Tailwinds

  • Liquidity and operating priorities are detailed in MD&A.
  • Pipeline or product milestones may support future revenue.

Headwinds

  • Operating losses and R&D spend pressure near-term earnings.
  • Financing or dilution risk if losses persist.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+10.9%

Avg return

Earnings day

+11.7%

Avg return

5 days after

+18.2%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+195.0%

Q2 2023

Best reaction

-16.0%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-3.5%-6.3%
Q1 2026+0.6%-1.6%-20.9%
Q3 2025-5.9%-8.9%+18.3%
Q2 2025+5.4%+6.5%+17.4%
Q1 2025+8.1%+23.6%+7.2%
Q4 2024-4.7%-4.7%+13.5%
Q3 2024-5.0%-4.6%-13.4%
Q2 2024+9.1%+7.7%+11.0%
Q1 2024+29.6%+28.7%+73.7%
Q4 2023+39.0%+52.6%+13.1%
Q3 2023+26.3%+27.8%+16.5%
Q2 2023+195.0%+159.8%+312.7%
Q1 2023-10.5%-7.7%+14.7%
Q4 2022-6.5%+14.8%-3.9%
Q3 2022-5.5%+9.0%+2.5%
Q2 2022-16.0%-16.4%-29.9%
Q1 2022-4.1%-19.5%-12.5%
Q4 2021+3.1%+8.5%-40.5%
Q3 2021+0.2%-3.1%-9.3%
Q2 2021+0.7%-2.6%+20.1%
Q1 2021-0.7%+2.0%+19.9%
Q4 2020-7.2%-0.2%-19.9%
Q3 2020+2.2%+4.0%+10.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro